Stocktoria
Ovid Therapeutics Inc. OVID
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-05-05
Ovid Therapeutics Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2025 | FY2024 | FY2024 | FY2024 |
|---|---|---|---|---|---|
| Operating margin | -585.2% | — | -10933.7% | — | — |
| Net margin | -240.1% | — | -4670.1% | — | — |
| FCF margin | -528.6% | — | -9898.8% | — | — |
| Return on assets | -11.5% | — | -28.7% | — | — |
| Return on equity | -13.3% | — | -38.7% | — | — |
| Current ratio | 8.97 | 4.93 | 5.32 | 5.66 | 5.73 |
| Revenue growth | -96.8% | 39405.3% | -99.7% | 0.1% | 0.1% |
Source: SEC EDGAR filings · CIK 0001636651 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.